Max Health stock hits a 52-week low as cancer drug caps spread

Published on 10/13/2026 at 11:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Max Healthcare reported Q1 FY27 revenue of INR 28.35 billion, up 15.2 percent year over year. Max Health stock faced 30 percent drug cap concerns.

Key points in brief

Max Health stock hit a 52-week low of INR 843 on October 13, 2026, amid concerns over possible cancer drug price caps.
Max Healthcare Network revenue reached INR 28.35 billion in Q1 FY27, up 15.2 percent year over year.
CARE Ratings reported Q1 FY27 PBILDT of INR 6.83 billion and a 25.31 percent margin.
The company operates 21 healthcare facilities with more than 6,100 beds, according to its investor-relations page.

Max Health, INE027H01010, Illustration mit AI erstellt.

Max Health stock hit a 52-week low of INR 843 on October 13, 2026, while Business Standard reported that possible government price caps on non-scheduled cancer drugs had added pressure to the hospital operator. The report said the stock had fallen 7 percent over three trading sessions and 20 percent over three weeks.

Three dated signals shape the stock

On August 13, 2026, Max Healthcare reported Q1 FY27 network revenue of INR 28.35 billion and PBILDT of INR 6.83 billion, compared with INR 24.60 billion and INR 5.91 billion in Q1 FY26, according to Economic Times. On October 12, 2026, CARE Ratings reaffirmed Max Healthcare's CARE AA+ and CARE A1+ ratings. On October 13, 2026, Business Standard linked the latest share-price weakness to reports of a possible 30 percent cap on cancer-drug markups.

What does regulation mean for margins?

CARE Ratings said Q1 FY27 PBILDT margin was 25.31 percent, compared with 26.96 percent for fiscal year 2026, while occupancy stood at 75.44 percent against 75.90 percent a year earlier. The agency expects operating margins to remain above 25 percent despite planned capacity expansion of 70 to 80 percent over the next four to five years.

The regulatory issue matters because Max Healthcare has exposure to government-linked patients and oncology treatments. Business Standard cited Jefferies as saying the potential earnings impact should be transitory, while CARE Ratings identified future regulation and reimbursement changes as key monitoring factors.

Expansion offsets the regulatory pressure

Max Healthcare's investor-relations page says the group operates 21 healthcare facilities with more than 6,100 beds and also runs Max@Home and Max Lab. CARE Ratings said the network had 5,214 operational beds as of June 30, 2026, with a plan to reach more than 10,000 beds by fiscal year 2030.

The market reaction is sharper than the operating trend: the October 13 low of INR 843 compared with a 52-week high of INR 1,221.10, while the one-year decline reached 25.30 percent, according to MarketsMojo. That gap leaves capacity growth and margin resilience as the central balance for the stock.

Stock level and investor context

Max Healthcare's market capitalization was INR 834.4 billion as of October 13, 2026. Its NSE ticker is MAXHEALTH, and the primary listing is on the National Stock Exchange of India.